Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
SAN FRANCISCO, Feb. 14, 2018 -- Hagens Berman Sobol Shapiro LLP alerts investors in Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) to the securities class action pending in the United States District Court for the Eastern District of New York and to the April 10, 2018 Lead Plaintiff deadline. If you purchased or otherwise acquired SGYP securities between September 5, 2017 and November 14, 2017 and suffered losses, contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/SGYP
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
The complaint charges Defendants with making false or misleading statements about the terms of a $300 million senior secured loan to Synergy from CRG Partners III L.P. More specifically, the Complaint charges Defendants falsely described this financing as non-dilutive to shareholders on September 5, 2017.
When Synergy filed the CRG loan agreement with the SEC on November 9, 2017, it revealed that the financing would likely be dilutive to shareholders. In response to this news, the price of Synergy shares fell $0.25, or about 8.4%, to close at $2.72 on November 10, 2017.
On November 14, 2017, Synergy filed a prospectus for the issuance of nearly 22 million shares and warrants to purchase nearly 22 million shares. In response, the price of Synergy shares fell $0.14, or about 6.9% to close at $1.89 on November 15, 2017.
“We’re focused on the Defendants’ statements about the financing’s impact on equity investors that, if false, damaged them,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Synergy Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
